Heather McArthur, MD

Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, comment on the role of preoperative endocrine therapy in HR-positive high-risk breast cancer.

Joyce O’Shaughnessy, MD, reviews the case of a 42-year-old woman with node-positive, HR-positive high-risk breast cancer and discusses clinical data from the POETIC and ADAPT clinical trials.

A panel of breast cancer experts share recommendations for adjuvant chemotherapy and endocrine therapy for a patient with HR-positive breast cancer and discuss approaches to toxicity management to increase adherence to therapy.

Joyce O’Shaughnessy, MD, leads a discussion on SABCS 2021 updates from the SOFT and TEXT trials for premenopausal women with HR-positive breast cancer.

Experts in breast cancer review the case of a 42-year-old woman with grade 2, node-positive invasive ductal carcinoma and discuss updated data from the RxPONDER trial on adjuvant chemotherapy benefit in premenopausal women.

Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, share insight on applying data presented from the monarchE study and the use of adjuvant abemaciclib in clinical practice for high-risk, HR+ early breast cancer.

Sunil Badve, MD, FRCPath, and Heather McArthur, MD, evaluate best practices around Ki67 assessment when approaching treatment for HR+ early breast cancer.

Joyce O’ Shaughnessy, MD; Sunil Badve, MD, FRCPath; and Massimo Cristofanilli, MD, FACP, consider the role of adjuvant abemaciclib plus endocrine therapy for the treatment of patients with high-risk, node-positive, HR+ early breast cancer.

Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’ Shaughnessy, MD, review the study design and clinical implications from the monarchE study for high-risk, HR+ early breast cancer.

Experts in breast cancer review the case of a 54-year-old postmenopausal woman with stage IIB, high-risk, HR+ early-stage breast cancer and discuss factors to consider when assessing risk for systemic occurrence.